{"paper_id":"31b72cea-8986-445f-bc16-810f23a11906","body_text":"Cancer Research and Experimental Oncology\n- Abbreviation: J. Cancer Res. Exp. Oncol.\n- Language: English\n- ISSN: 2141-2243\n- DOI: 10.5897/JCREO\n- Start Year: 2009\n- Published Articles: 59\nShort Communication\n- Hematology Department, Chu Mohamed VI, University Cadi Ayyad, Marrakech, Morocco.\n- Search for this author on:\n- Google Scholar\n- Hematology Department, Chu Mohamed VI, University Cadi Ayyad, Marrakech, Morocco.\n- Search for this author on:\n- Google Scholar\n- Hematology Department, Chu Mohamed VI, University Cadi Ayyad, Marrakech, Morocco.\n- Search for this author on:\n- Google Scholar\n- Article Number - 0B114013971\n- Vol.3(2), pp. 20-21 , February 2011\n- https://doi.org/10.5897/JCREO.9000017\n- Accepted: 25 January 2011\n- Published: 28 February 2011\nCopyright © 2026 Author(s) retain the copyright of this article.\nThis article is published under the terms of the Creative Commons Attribution License 4.0.\nAbstract\nThe management of Evan’s syndrome remains a challenge and innovative approaches are needed. Initial therapeutic failure, relapses after initial response and refractoriness to treatments are typical. Options for second-line therapy include immunosuppressive drugs, especially cyclosporin or mycophenolate mofetil; vincristine; danazol or a combination of these agents. We report here a long-term remission of Evan’s syndrome obtained with 6-mercaptopurine in a 35-year-old female patient.\nKey words: 6-Mercaptopurine, Evan’s syndrome, remission.\nCopyright © 2026 Author(s) retain the copyright of this article.\nThis article is published under the terms of the Creative Commons Attribution License 4.0","source_license":"CC0","license_restricted":false}